Our findings provide compelling evidence of the ability of ISRIB to enhance the activity and maturation of glial cells in eIF2B‐mutant organoids, thereby supporting its potential as a novel drug for VWM. This evidence concerns the gene EIF2B1 and leukoencephalopathy with vanishing white matter.